SOUTH SAN FRANCISCO, Calif. — January 14, 2026 — Leads & Copy — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company, announced its participation in a Virtual Investor CEO Connect Segment.
Timothy Lu, MD, PhD, CEO of Senti Bio, discussed the recent FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted to SENTI-202. SENTI-202 is the company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. It is currently in development for the treatment of relapsed/refractory hematologic malignancies, including AML.
The RMAT designation builds on the Orphan Drug Designation that the FDA granted SENTI-202 in June. Dr. Lu also discussed new data from 20 patients (18 with evaluable responses) in its ongoing multinational, multicenter clinical trial of SENTI-202 in patients with relapsed or refractory AML. The data were recently presented at the American Society of Hematology (ASH) Annual Meeting in Orlando.
Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration.
The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
For more information, please visit the Senti Bio website or follow Senti Bio on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn.
Investors:
investors@sentibio.com
Media:
media@sentibio.com
Investor Contact:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
snti@jtcir.com
Source: Senti Biosciences, Inc.